Actively Recruiting
Study of Realgar Indigo Naturalis Formula Combined with Chemotherapy for Children Aged 1 to 14 With Relapsed Intermediate or High Risk Acute Lymphoblastic Leukemia
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2023-01-12
210
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatments for children aged 1 to 14 years with relapsed acute lymphoblastic leukemia ALL, focusing on those with intermediate or high risk. Although outcomes have improved, the 5-year overall survival rate for first recurrence remains below 50%. This study explores whether adding the Realgar Indigo naturalis formula, a traditional Chinese medicine containing arsenic tetrasulfide similar to arsenic trioxide, can improve outcomes when combined with conventional chemotherapy. The trial is a phase 4, double-blind, randomized controlled study comparing conventional chemotherapy plus either an oral placebo or the Realgar Indigo naturalis formula. Participants receive the study drug during induction, consolidation, and intensive treatment phases according to the UK ALL R3 protocol. The goal is to improve the minimal residual disease MRD negative rate after induction therapy in children with intermediate or high risk relapsed ALL. Participants will be monitored for response to treatment with the primary outcome measuring the complete response rate about 7 weeks from diagnosis. This includes regular assessments during induction therapy and follow-up to evaluate treatment effects. The study is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University and plans to continue until 2030, providing detailed monitoring of treatment impact and safety in this population.
CONDITIONS
Brief Title
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
Research Team
P
Pei J Fang, Doctoral
J
Jian Wang, Master's
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here